SMU-037

SMU-037: sourced facts only. name: "The preferred compound SMU-037 demonstrates nanomolar inhibition against the ROS1 enzyme and approximately 25-fold selectivity over ALK." [PMID:40907378]; target: "The preferred compound SMU-037 demonstrates nanomolar inhibition against the ROS1 enzyme and approximately 25-fold selectivity over ALK." [PMID:40907378]; developer: "NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China." [PMID:40907378]; stage: "Additionally, SMU-037 effectively suppresses tumor progression in both xenograft and intracranial models, exhibiting enhanced penetration into the central nervous system and resulting in a substantial reduction of brain lesions." [PMID:40907378]